Simcere agrees to $495.4M buyout deal

China's Simcere Pharmaceutical (SCR) has agreed to be taken private by a consortium that includes founder and Chairman Jinsheng Ren in a deal worth $495.4M.

The buyout group, which already owns 78% of the company, is offering $9.66 per ADS, or a premium of 3% to the company's close of $9.36 yesterday. The price is also above a previous offer of $9.56. (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs